Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI)...

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

WEDNESDAY, Sept. 18, 2024 -- Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following...

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer,...

Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative breast cancer patients.

TUESDAY, Sept. 17, 2024 -- For postoperative patients with breast cancer, the duration of aromatase inhibitor (AI) treatment is not associated with...

Caring for cancer patients, particularly those with breast cancer, is in focus in several research projects at the University of Borås, Sweden.

New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who received...

MONDAY, Sept. 9, 2024 -- Cancer diagnosis is associated with an increased risk for psychological illness and cardiovascular disease among...

Young women of African descent risk a more aggressive form of breast cancer disease, known as triple-negative breast cancer.